Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $21.67.

Several research firms have recently commented on NMRA. Needham & Company LLC reiterated a "buy" rating and set a $23.00 target price on shares of Neumora Therapeutics in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Neumora Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. cut Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, September 4th.

Insider Buying and Selling at Neumora Therapeutics

In other news, CFO Joshua Pinto sold 31,642 shares of the company's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the transaction, the chief financial officer now owns 154,658 shares in the company, valued at $1,821,871.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at approximately $342,303. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joshua Pinto sold 31,642 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares in the company, valued at $1,821,871.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,538 shares of company stock valued at $1,390,513. 26.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NMRA. Price T Rowe Associates Inc. MD acquired a new position in Neumora Therapeutics during the first quarter valued at approximately $10,354,000. Callan Capital LLC grew its holdings in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company's stock valued at $6,500,000 after purchasing an additional 456,207 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Neumora Therapeutics by 79.5% during the second quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company's stock valued at $1,099,000 after purchasing an additional 49,527 shares during the last quarter. Rhumbline Advisers grew its holdings in Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company's stock valued at $1,015,000 after purchasing an additional 85,706 shares during the last quarter. Finally, Auour Investments LLC acquired a new position in Neumora Therapeutics during the third quarter valued at approximately $3,302,000. Institutional investors and hedge funds own 47.65% of the company's stock.

Neumora Therapeutics Trading Down 4.7 %

NASDAQ:NMRA traded down $0.54 during trading hours on Wednesday, hitting $10.78. The stock had a trading volume of 1,358,458 shares, compared to its average volume of 725,071. The company has a market cap of $1.72 billion, a PE ratio of -5.91 and a beta of 3.92. The business has a 50 day simple moving average of $13.08 and a two-hundred day simple moving average of $11.41. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same quarter in the prior year, the firm posted ($1.14) earnings per share. Research analysts expect that Neumora Therapeutics will post -1.48 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.